Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2022 call → NOWe need to determine if management's forward account is substantially about counterparties' own scaling. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look at the transcript. Management discusses various things: SOFR transition, international growth, retail, market data, cloud migration, etc. But the key is whether they describe specific counterparties' own ramps as the driver of CME's future. For example, in the SOFR discussion, they talk about adoption of SOFR futures and options, and they mention that they have licensed CME term SOFR to 1,300 firms across 74 countries, and it's being used in $1.6 trillion worth of cash market products. That is about their own product adoption, but it's about their own product being used by many counterparties. However, the question is about whether management narrates what those counterparties are themselves doing and scaling. They mention that they have licensed to 1,300 firms, but they don't describe those firms' own expansion plans. They talk about the transition from LIBOR to SOFR, which is a market-wide shift, but they don't describe specific counterparties' own build-outs. In the international growth discussion, they talk about growth in various regions, but they attribute it to their own efforts, cross-selling, new products, etc. They mention that they have regional client-facing resources, and they are seeing growth in areas. They don't describe specific counterparties' own trajectories. In the retail discussion, they talk about their own initiatives, like event contracts, and they mention that they are working with broker partners, but they don't describe those partners' own scaling. In the market data discussion, they talk about licensing term SOFR to many firms, but again, that's about their own product adoption.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.